pharmaphorum October 25, 2024
GSK has made another investment in its manufacturing network, setting aside $800 million to build two plants at its Marietta site in the US.
The programme represents the largest capital spend by the UK drugmaker on production capacity to date and will double the size and capacity of GSK’s existing medicines and vaccines facility in Marietta, Pennsylvania, creating around 200 new jobs.
The centrepiece of the new investment is a multi-purpose facility capable of manufacturing sterile liquid vaccines and medicines, for which GSK says there is “ever increasing demand,” and a vaccine drug substances plant that will support the multiple antigen presenting system (MAPS) technology that GSK acquired as part of its $3.3 billion takeover of Affinivax in 2022.
Also...
Today's Sponsors
Today's Sponsor